[go: up one dir, main page]

DE3775301D1 - Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien. - Google Patents

Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.

Info

Publication number
DE3775301D1
DE3775301D1 DE8787830298T DE3775301T DE3775301D1 DE 3775301 D1 DE3775301 D1 DE 3775301D1 DE 8787830298 T DE8787830298 T DE 8787830298T DE 3775301 T DE3775301 T DE 3775301T DE 3775301 D1 DE3775301 D1 DE 3775301D1
Authority
DE
Germany
Prior art keywords
acetyl
carnitin
medicine
producing
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787830298T
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE3775301D1 publication Critical patent/DE3775301D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE8787830298T 1986-08-04 1987-07-31 Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien. Expired - Lifetime DE3775301D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48358/86A IT1196564B (it) 1986-08-04 1986-08-04 Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche

Publications (1)

Publication Number Publication Date
DE3775301D1 true DE3775301D1 (de) 1992-01-30

Family

ID=11266089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787830298T Expired - Lifetime DE3775301D1 (de) 1986-08-04 1987-07-31 Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.

Country Status (11)

Country Link
US (1) US4751242A (de)
EP (1) EP0256999B1 (de)
JP (1) JPH085786B2 (de)
AT (1) ATE70439T1 (de)
CA (1) CA1298197C (de)
DE (1) DE3775301D1 (de)
DK (1) DK164641C (de)
ES (1) ES2039262T3 (de)
GR (1) GR3003405T3 (de)
IT (1) IT1196564B (de)
ZA (1) ZA875643B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
US5641764A (en) * 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1244636B (it) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
JPH11298323A (ja) 1998-04-16 1999-10-29 Nec Yamagata Ltd 高速ロックアップｐｌｌ回路
EP1100589B1 (de) * 1998-07-30 2005-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
AU7828200A (en) * 1999-09-23 2001-04-24 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) * 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
ES2425045T3 (es) * 2005-04-26 2013-10-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
US20080161604A1 (en) * 2005-04-26 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8569366B2 (en) 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
MX2012014127A (es) 2010-06-16 2013-06-28 Sigma Tau Ind Farmaceuti Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso.
EP3277273B1 (de) * 2015-03-31 2020-02-26 Kolinpharma S.p.A. Zusammensetzungen zur behandlung von neuropathien und/oder neuropathischen schmerzen
WO2017139415A2 (en) * 2016-02-11 2017-08-17 Qiagen Waltham, Inc. Scavenger compounds for improved sequencing-by-synthesis
MX2022012693A (es) 2020-05-15 2022-11-07 Alfasigma Spa Composicion que comprende metilfolato.
IT202200022437A1 (it) 2022-11-02 2024-05-02 Chiesi Italia S P A Composizione farmaceutica comprendente l-acetilcarnitina e beta-cariofillene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
DK403587A (da) 1988-02-05
CA1298197C (en) 1992-03-31
DK164641B (da) 1992-07-27
ZA875643B (en) 1988-11-30
JPS6344522A (ja) 1988-02-25
EP0256999A3 (en) 1989-05-31
EP0256999A2 (de) 1988-02-24
IT1196564B (it) 1988-11-16
US4751242A (en) 1988-06-14
EP0256999B1 (de) 1991-12-18
JPH085786B2 (ja) 1996-01-24
DK164641C (da) 1992-12-14
ES2039262T3 (es) 1993-09-16
DK403587D0 (da) 1987-08-03
IT8648358A0 (it) 1986-08-04
GR3003405T3 (en) 1993-02-17
ATE70439T1 (de) 1992-01-15

Similar Documents

Publication Publication Date Title
DE3775301D1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE292463T1 (de) L-carnitin oder ihre derivate und resveratrol oder ihre derivate zur vorbeugung und behandlung von kardiovaskulären erkrankungen, peripheren gefässkrankheit, peripheren diabetischen neuropathie und diese enthaltende pharmazeutische zusammensetzungen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
MY101207A (en) Treatment of diseases caused by retroviruses
ATE287278T1 (de) Verwendung von propionyl-l-carnitin und acetyl-l- carnitin zur herstellung von arzneimittel mit antikrebs wirkung
DE68911891D1 (de) Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung.
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
DE68908145D1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE79749T1 (de) Verwendung von einigen alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur therapeutischen behandlung von ideopathischem oder induziertem parkinsonismus.
DE3781054D1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
KR890000108A (ko) 종양 치료용 약제학적 조성물
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
ATE121623T1 (de) Verwendung von quinazolinen zur herstellung eines arzneimittels zur behandlung und vorbeugung von arrhythmie.
ATE105192T1 (de) Methode fuer die kontrolle von chronischer atmungskrankheit und nekrotischer enteritis bei voegeln.
ATE73326T1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.
RU92013625A (ru) Лекарственное средство, стимулирующее эритроидный росток кроветворения при цитостатических миелодепрессиях
DE3579642D1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition